超声评价阿普米司特治疗银屑病关节炎的疗效：关节、全身和指甲指数

IF 1.3 Q4 RHEUMATOLOGY

Reumatologia Clinica Pub Date : 2025-08-01 DOI:10.1016/j.reuma.2025.501921

Juan José de Agustin , Gustavo Adolfo Añez , Delia Reina , Sergi Heredia , Julio Ramirez , Andrea Mireya Cuervo , Jesus Rodriguez , Carmen Moragues , Patricia Moya , Ana Maria Laiz Alonso , Mireia Moreno , Marta Arevalo , Manel Pujol , Georgina Salvador , Noemi Busquets , Andres Ponce , Maria Pascual Pastor

{"title":"超声评价阿普米司特治疗银屑病关节炎的疗效：关节、全身和指甲指数","authors":"Juan José de Agustin , Gustavo Adolfo Añez , Delia Reina , Sergi Heredia , Julio Ramirez , Andrea Mireya Cuervo , Jesus Rodriguez , Carmen Moragues , Patricia Moya , Ana Maria Laiz Alonso , Mireia Moreno , Marta Arevalo , Manel Pujol , Georgina Salvador , Noemi Busquets , Andres Ponce , Maria Pascual Pastor","doi":"10.1016/j.reuma.2025.501921","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Psoriatic arthritis (PsA) affects joints and entheses. The objective is to use ultrasound (US) to see inflammatory changes in joints and entheses in patients with active PsA starting Apremilast. Primary objective: 20% reduction in the US index (UIC) at 12 months.</div></div><div><h3>Methodology</h3><div>Multicenter, prospective, open-label study. Patients with PsA (≥2 swollen joints) and ≥2 US synovitis in joints and ≥1 US enthesitis at screening were recruited. Follow-up was 52 weeks (baseline and 1, 6, 9, 12 months). US (joint, tendon, and entheses), clinical (SJC, TJC, LEI, PGA, PtGA), and biological (ESR and CRP) parameters were recorded.</div></div><div><h3>Results</h3><div>48 patients were evaluated, 46 were included in the follow-up and 26 completed the 52-week study. The primary endpoint was achieved, with reductions of up to 40%. All clinical and ultrasound variables decreased significantly after 12 months. 75 adverse events (AEs) were recorded in 33 patients, and only one serious event (SAE). Reasons for withdrawal included AEs (6 patients), lack of efficacy (8 patients), and other reasons (loss to follow-up, withdrawal of consent) for 6 patients.</div></div><div><h3>Conclusions</h3><div>Changes in different domains of PsA in patients treated with Apremilast can be best identified by ultrasound. Ultrasound is an excellent tool to study joints, tendons, and entheses in PsA. Apremilast is a safe, well-tolerated, and effective treatment for several patterns of PsA (joints, entheses) as demonstrated by ultrasound. Ultrasound can also identify nail diseases in patients with PsA.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 7","pages":"Article 501921"},"PeriodicalIF":1.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Usefulness of ultrasound in the assessment of the efficacy of apremilast in psoriatic arthritis: Articular, enthesitic and nail index\",\"authors\":\"Juan José de Agustin , Gustavo Adolfo Añez , Delia Reina , Sergi Heredia , Julio Ramirez , Andrea Mireya Cuervo , Jesus Rodriguez , Carmen Moragues , Patricia Moya , Ana Maria Laiz Alonso , Mireia Moreno , Marta Arevalo , Manel Pujol , Georgina Salvador , Noemi Busquets , Andres Ponce , Maria Pascual Pastor\",\"doi\":\"10.1016/j.reuma.2025.501921\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Psoriatic arthritis (PsA) affects joints and entheses. The objective is to use ultrasound (US) to see inflammatory changes in joints and entheses in patients with active PsA starting Apremilast. Primary objective: 20% reduction in the US index (UIC) at 12 months.</div></div><div><h3>Methodology</h3><div>Multicenter, prospective, open-label study. Patients with PsA (≥2 swollen joints) and ≥2 US synovitis in joints and ≥1 US enthesitis at screening were recruited. Follow-up was 52 weeks (baseline and 1, 6, 9, 12 months). US (joint, tendon, and entheses), clinical (SJC, TJC, LEI, PGA, PtGA), and biological (ESR and CRP) parameters were recorded.</div></div><div><h3>Results</h3><div>48 patients were evaluated, 46 were included in the follow-up and 26 completed the 52-week study. The primary endpoint was achieved, with reductions of up to 40%. All clinical and ultrasound variables decreased significantly after 12 months. 75 adverse events (AEs) were recorded in 33 patients, and only one serious event (SAE). Reasons for withdrawal included AEs (6 patients), lack of efficacy (8 patients), and other reasons (loss to follow-up, withdrawal of consent) for 6 patients.</div></div><div><h3>Conclusions</h3><div>Changes in different domains of PsA in patients treated with Apremilast can be best identified by ultrasound. Ultrasound is an excellent tool to study joints, tendons, and entheses in PsA. Apremilast is a safe, well-tolerated, and effective treatment for several patterns of PsA (joints, entheses) as demonstrated by ultrasound. Ultrasound can also identify nail diseases in patients with PsA.</div></div>\",\"PeriodicalId\":47115,\"journal\":{\"name\":\"Reumatologia Clinica\",\"volume\":\"21 7\",\"pages\":\"Article 501921\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reumatologia Clinica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1699258X25001159\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia Clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699258X25001159","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景银屑病关节炎（PsA）影响关节和关节。目的是使用超声（US）来观察开始使用阿普拉米司特的活性PsA患者关节和关节的炎症变化。主要目标：12个月内美国指数（UIC）降低20%。方法：多中心、前瞻性、开放标签研究。筛查时伴有PsA（≥2个关节肿胀）、≥2个关节US滑膜炎和≥1个US腱鞘炎的患者。随访52周（基线及1、6、9、12个月）。记录US（关节、肌腱和关节）、临床（SJC、TJC、LEI、PGA、PtGA）和生物学（ESR和CRP）参数。结果48例患者接受评估，46例纳入随访，26例完成了52周的研究。主要终点达到了，减少了40%。12个月后，所有临床和超声指标均显著下降。33例患者记录了75例不良事件（ae），仅1例严重事件（SAE）。停药原因包括ae（6例）、缺乏疗效（8例）和其他原因（失去随访、撤回同意）6例。结论阿普米司特治疗后PsA不同区域的变化可通过超声诊断。超声是一种很好的工具来研究关节，肌腱和关节在PsA。阿普拉米司特是一种安全，耐受性良好，有效的治疗多种类型的PsA（关节，关节）的超声证实。超声也可以识别PsA患者的指甲疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Usefulness of ultrasound in the assessment of the efficacy of apremilast in psoriatic arthritis: Articular, enthesitic and nail index

Background

Psoriatic arthritis (PsA) affects joints and entheses. The objective is to use ultrasound (US) to see inflammatory changes in joints and entheses in patients with active PsA starting Apremilast. Primary objective: 20% reduction in the US index (UIC) at 12 months.

Methodology

Multicenter, prospective, open-label study. Patients with PsA (≥2 swollen joints) and ≥2 US synovitis in joints and ≥1 US enthesitis at screening were recruited. Follow-up was 52 weeks (baseline and 1, 6, 9, 12 months). US (joint, tendon, and entheses), clinical (SJC, TJC, LEI, PGA, PtGA), and biological (ESR and CRP) parameters were recorded.

Results

48 patients were evaluated, 46 were included in the follow-up and 26 completed the 52-week study. The primary endpoint was achieved, with reductions of up to 40%. All clinical and ultrasound variables decreased significantly after 12 months. 75 adverse events (AEs) were recorded in 33 patients, and only one serious event (SAE). Reasons for withdrawal included AEs (6 patients), lack of efficacy (8 patients), and other reasons (loss to follow-up, withdrawal of consent) for 6 patients.

Conclusions

Changes in different domains of PsA in patients treated with Apremilast can be best identified by ultrasound. Ultrasound is an excellent tool to study joints, tendons, and entheses in PsA. Apremilast is a safe, well-tolerated, and effective treatment for several patterns of PsA (joints, entheses) as demonstrated by ultrasound. Ultrasound can also identify nail diseases in patients with PsA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Reumatologia Clinica RHEUMATOLOGY-

CiteScore

2.40

自引率

6.70%

发文量

105

审稿时长

54 days

期刊介绍： Una gran revista para cubrir eficazmente las necesidades de conocimientos en una patología de etiología, expresividad clínica y tratamiento tan amplios. Además es La Publicación Oficial de la Sociedad Española de Reumatología y del Colegio Mexicano de Reumatología y está incluida en los más prestigiosos índices de referencia en medicina.